The dysmetabolic syndrome

Journal of Internal Medicine

Volumn 250, Issue 2, 2001, Pages 105-120

  Groop, L ^a,b   Orho Melander, M ^a  

^a LUND UNIVERSITY   (Sweden)

^b LUND UNIVERSITY HOSPITAL   (Sweden)

Author keywords

Abdominal obesity; Dyslipidaemia; Hypertension; Insulin resistance; Thrifty genes; Type 2 diabetes

Indexed keywords

BETA 1 ADRENERGIC RECEPTOR; BETA 2 ADRENERGIC RECEPTOR; FATTY ACID BINDING PROTEIN; FURIN; GLYCOGEN SYNTHASE; GLYCOPROTEIN; INSULIN RECEPTOR SUBSTRATE 1; INSULIN RECEPTOR SUBSTRATE 2; LEPTIN; LEPTIN RECEPTOR; MELANOCORTIN RECEPTOR; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; PROOPIOMELANOCORTIN; TRIACYLGLYCEROL LIPASE; TUMOR NECROSIS FACTOR ALPHA; UNCOUPLING PROTEIN;

DISEASE PREDISPOSITION; DYSLIPIDEMIA; GENE CONTROL; GENETIC ANALYSIS; GLUCOSE TRANSPORT; HUMAN; HYPERTENSION; IMPAIRED GLUCOSE TOLERANCE; INSULIN RESISTANCE; METABOLIC DISORDER; MICROALBUMINURIA; MORTALITY; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; OBESITY; PREVALENCE; PRIORITY JOURNAL; REVIEW; RISK; SKELETAL MUSCLE; SURVIVAL; THERMOGENESIS;

ABDOMEN; ADULT; AGE DISTRIBUTION; AGED; ANIMALS; CARRIER PROTEINS; DIABETES MELLITUS, TYPE 2; GENOTYPE; HUMANS; HYPERLIPIDEMIAS; HYPERTENSION; INSULIN RESISTANCE; LEPTIN; MIDDLE AGED; MUTATION; OBESITY; PHENOTYPE; PREVALENCE; PRO-OPIOMELANOCORTIN; RECEPTOR, MELANOCORTIN, TYPE 4; RECEPTORS, CELL SURFACE; RECEPTORS, PEPTIDE; SYNDROME;

EID: 0034825009     PISSN: 09546820     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-2796.2001.00864.x     Document Type: Review

References (158)

1. Role of insulin resistance in human disease
2. Studien ueber das hypertonie-hyperglykämie-hyperurikämiesyndrom
3. Insulin resistance. A multifacet syndrome responsible for NIDDM, obesity, hypertension, dyslipidemia and atherosclerotic cardiovascular disease
4. Hyperinsulinemia: A link between hypertension, obesity and glucose intolerance
5. Prospective analysis of the insulin-resistance syndrome (Syndrome X)
6. Risk variable clustering in the insulin resistance syndrome. The Framingham offspring study
7. Comments on the provisional report from the WHO consultation
8. Prevalence of insulin resistance in metabolic disorders. The Bruneck Study
9. Prevalence of the metabolic syndrome in drug-treated hypertensive patients and control subjects
10. Insulin sensitivity and acute insulin response in African-Americans, non-Hispanic whites and Hispanics with NIDDM: The insulin resistance atherosclerosis study
11. Definition, diagnosis and classification of diabetes mellitus and its complications. Part 1: Diagnosis and classification of diabetes mellitus, provisional report of a WHO consultation
12. Cardiovascular morbidity and mortality associated with the metabolic syndrome
13. Metabolic consequences of a family history of NIDDM (The Botnia Study)
14. Metabolic and genetic characterization of prediabetic states. Sequence of events leading to non-insulin-dependent diabetes mellitus
15. Non-insulin-dependent diabetes mellitus - A collision between thrifty genes and an affluent society
16. Early metabolic defects in persons at increased risk for non-insulin-dependent diabetes mellitus
17. Inheritance of the amount and distribution of human body fat
18. Genetics of body fat content
19. Genetic influences on central abdominal fat: A twin study
20. Independent genetic factors determine the amount and distribution of fat in women after the menopause
21. Insulin resistance in essential hypertension
22. Familial clustering of insulin and abdominal visceral fat: The HERITAGE family study
23. Insulin secretion and insulin sensitivity in monozygotic and dizygotic twins
24. Insulin resistance in Type 2 diabetic patients with hypertriglyceridemia
25. Albumin excretion is an inherited trait in families with NIDDM?
26. Insulin resistance and abnormal albumin excretion in non-diabetic first-degree relatives of patients with NIDDM
27. Microalbuminuria is associated with insulin resistance in nondiabetic subjects
28. Insulin resistance, hypertension and microalbuminuria in patients with Type 2 diabetes mellitus
29. Insulin resistance is related to albuminuria in patients with type II (non-insulin-dependent) diabetes mellitus
30. Does intraabdominal adipose tissue in black men determine whether NIDDM is insulin-resistant or insulin-sensitive?
31. Positional cloning of the mouse obese gene and its human homologue
32. Adipose expression of tumor necrosis factor-α: Direct role in obesity-linked insulin resistance
33. Increased adipose tissue expression of tumor necrosis factor-α in human obesity and insulin resistance
34. Influence of dietary fat composition on development of insulin resistance in rats. Relationship to muscle triglyceride and omega-3 fatty acids in muscle phospholipid
35. Are skeletal muscle triglycerides the culprint behind insulin resistance
36. Insulin action and substrate competition
37. Diabetes mellitus: A 'thrifty' genotype rendered detrimental by progress?
38. Obesity genes: Beneficial effects in hetrozygous mice
39. Type 2 diabetes mellitus: The thrifty phenotype hypothesis
40. Heredity for hypertension influences intrauterine growth and the relation between foetal growth and adult blood pressure
41. Mutations in the glucokinase gene of the fetus result in reduced birth weight
42. The diastrophic dysplasia gene encodes a novel sulfate transporter: Positional cloning by fine-structure linkage disequilibrium mapping
43. Effects of the obese gene product on body weight regulation in ob/ob mice
44. Evidence against either a premature stop codon or the absence of obese gene mRNA in human obesity
45. Leptin levels in human and rodent: Measurement of plasma leptin and ob RNA in obese and weight-reduced subjects
46. Molecular cloning of rat obese cDNA and augmented gene expression in genetically obese Zucker fatty (fa/fa) rats
47. Overexoression of the obese gene (ob) in adipose tissue of human obese subjects
48. Congenital leptin deficiency is associated with severe early-onset obesity in humans
49. A leptin missense mutation associated with hypogonadism and morbid obesity
50. Effects of recombinant leptin therapy in a child with congenital leptin deficiency
51. Recombinant leptin for weight loss in obese and lean adults: A randomized, controlled, dose-escalation trial
52. Identification and expression cloning of a leptin receptor, ob-R
53. Leptin and the regulation of body weight in mammals
54. A mutation in the leptin receptor gene causes obesity and pituitary dysfunction
55. A common pentanucleotide polymorphism of the 3′-untranslated part of the leptin receptor gene generates a putative stem-loop motif in the mRNA and is associated with serum insulin levels in obese individuals
56. A frameshift mutation in human MCR4 is associated with a dominant form of obesity
57. A frameshift mutation in MCR4R associated with dominantly inherited human obesity
58. Several mutations in the melanocortin-4 receptor gene including a nonsense and a frameshift mutation associated with dominantly inherited obesity in humans
59. Melanocortin-4 receptor mutations are a frequent and heterogeneous cause of morbid obesity
60. Dominant and recessive inheritance of morbid obesity associated with melanocortin 4 receptor deficiency
61. A major quantitative trait locus determining serum leptin levels and fat mass is located on human chromosome 2
62. Linkage and association studies between the melanocortin receptor-4 and receptor-5 genes and obesity-related phenotypes in the Quebec family study
63. Normal variation in leptin levels in associated with polymorphisms in the proopiomelanocortin gene, POMC
64. Severe early-onset obesity, adrenal insufficiency and red hair pigmentation caused by POMC mutations in humans
65. Systematic mutation screening of the pro-opiomelanocortin gene: Identification of several genetic variants including three different insertions, one nonsense and two missense point mutations in probands of different weight extremes
66. Linkage and association studies between the proopiomelanocortin (POMC) gene and obesity in caucasian families
67. Hyperproinsulinemia in obese fat/fat mice associated with a carboxypeptidase E mutation which reduces enzyme activity
68. Obesity and impaired prohormone processing associated with mutations in the human prohormone convertase 1 gene
69. Molecular characterization of the human beta-3-adrenergic receptor
70. Development of obesity in transgenic mice after genetic ablation of brown adipose tissue
71. Tissue distribution of beta-3-adrenergic receptor mRNA in man
72. A pathogenetic role of visceral fat beta-3-adrenoreceptors in obesity
73. Time of onset of non-insulin-dependent diabetes mellitus and genetic variation in the beta3-adrenergic-receptor gene
74. Association of a polymorphism in the beta-3-adrenergic-receptor gene with features of the insulin resistance syndrome in Finns
75. Genetic variation in the beta3-adrenergic receptor and an increased capacity to gain weight in patients with morbid obesity
76. Polymorphism of the beta-3-adrenergic receptor gene affects basal metabolic rate in obese Finns
77. The association between Trp 64Arg polymorphism of the beta-3-adrenergic receptor and autonomic nervous system activity
78. The Trp64Arg mutation of the beta-3-adrenergic receptor gene has no effect on obesity phenotypes in the Quebec family study and Swedish Obese subjects cohort
79. Association of Trp64Arg mutation of the beta3-adrenergic receptor with NIDDM and body weight gain
80. Meta-analysis of the association of the Trp64Arg polyomorphism of the beta-3-adrenergic receptor gene with body mass index
81. Genetic polymorphism and disease
82. A paired sibling analysis of the beta-3 adrenergic receptor and obesity in Mexican americans
83. A quantitative trait locus influencing BMI maps to the region of beta-3-adrenergic receptor
84. The biological effect of the naturally occurring Trp64-Arg mutation on human beta-3-adrenoceptor activity
85. Polymorphism of the human beta-3-adrenoceptir gene forms a well-conserved haplotype that is associated with moderate obesity and altered receptor function
86. Beta-3-adrenergic receptor polymorphism: A genetic marker for visceral fat obesity and the insulin resistance syndrome
87. A high concentration of fasting plasma nonesterified fatty acids is a risk factor for the development of NIDDM
88. The role of nonesterified fatty acids in the deterioration of glucose tolerance in Caucasian subjects: Results of the Paris Prospective Study
89. Common variants in the beta2-(Gln27Glu) and beta3-(Trp64Arg)-adrenoceptor genes are associated with elevated NEFA levels and type 2 diabetes
90. Molecular and genetic basis of beta2-adrenergic receptor function
91. Human beta-2-adrenoceptor gene polymorphisms are highly frequent in obesity and associate with altered adiipocyte beta-2-adrenoceptor function
92. Beta-2-adrenergic receptor gene variations and hypertension in subjects with type 2 diabetes
93. A gain-of-function polymorphism in a G-protein coupling domain of the human beta-1-adrenergic receptor
94. Polymorphism in the beta-1 adrenergic receptor and hypertension
95. Linkage of chromosomal markers on 4q with a putative gene determining maximal insulin action in Pima Indians
96. An amino acid substitution in the human intestinal fatty acid binding protein is associated with increased fatty acid binding, increased fat oxidation and insulin resistance
97. Evidence for linkage of postchallenge insulin levels with intestinal fatty-acid-binding protein (FAB2) in Mexican americans
98. Intestinal fatty acid-binding protein variation associated with variation in the response of plasma lipoproteins to dietary fibre
99. Association between Ala54Thr substitution of the fatty acid-binding protein 2 gene with insulin resistance and intra-abdominal fat thickness in Japanese men
100. Postprandial lipemic response is modified by the polymorphism at codon 54 of the fatty acid-binding protein 2 gene
101. The T 54 allele of the intestinal fatty acid-binding protein 2 is associated with a parental history of stroke
102. The putative role of the hormone sensitive lipase gene in the pathogenesis of the metabolic syndrome
103. A lipoprotein lipase mutation (Asn291Ser) is associated with reduced HDL cholesterol levels in premature atherosclerosis
104. The Asn291Ser and Ser-477-stop mutations of the lipoprotein lipase gene and their significance for lipid metabolism in patients with hypertriglyceridemia
105. Interaction between the Asn291Ser variant of the LPL gene and insulin resistance on dyslipidaemia in high risk individuals for Type 2 diabetes mellitus
106. Association of variation in hepatic lipase activity with promoter variation in the hepatic lipase gene
107. Mice lacking mitochondrial uncoupling protein are cold-sensitive but not obese
108. Uncoupling protein 3: A member of the mitochondrial carrier family with tissue specific expression
109. UCP3: An uncoupling protein homolgue expressed in preferentially and abundantly in skeletal muscle and brown adipose tissue
110. Additve effect of A-G (-3826) variant of the uncoupling protein gene and the Trp64Arg mutation of the beta-3-adrenergic receptor gene on weight gain in morbid obesity
111. Additive effect of the mutations in the beta-3-adrenergic receptor and uncoupling protein-1 genes on weight loss and weight maintenance in Finnish Women
112. Synergistic effect of polymorphisms in uncoupling protein 1 and beta3-adrenergic receptor genes on long-term body weight change in Finnish type 2 diabetic and non-diabetic control subjects
113. Synergistic effect of polymorphisms in uncoupling protein 1 and beta-3-adrenergic receptor genes on basal metabolic rate in obese Finns
114. No relationship between variants in the uncoupling protein 2 gene and energy expenditure
115. Genetic and physiologic analysis of the role of uncoupling protein 3 in human energy homeostasis
116. Disruption of the uncoupling protein-2 gene in mice reveals a role in immunity and reactive oxygen species production
117. Lack of obesity and normal response to fasting and thyroid hormone in mice lacking uncoupling protein-3
118. Energy metabolism in uncoupling protein 3 gene knockout mice
119. Effects of mutations in the human uncoupling protein 3 gene on the respiratory quotient and fat oxidation in severe obesity and type 2 diabetes
120. Endogenous mutations in human uncoupling protein 3 alter its functional properties
121. Circulating TNF-alpha and leptin levels in offspring of NIDDM patients do not correlate to individual insulin sensitivity and insulin sensitivity in man
122. The expression of TNF-alpha by human muscle. Relationship to insulin resistance
123. The TNF-alpha gene Nco I polymorphism influences the relationship among insulin resistance, percent body fat, and increased serum leptin levels
124. Tumor necrosis factor-alpha-238 and-308 polymorhisms do not associate with traits related to obesity and insulin resistance
125. The common PPARgamma Pro12Ala polymorphism is associated with decreased risk of type 2
126. PPARgamma, the ultimate thrifty gene
127. Obesity associated with a mutation in a genetic regulator of adipocyte differentiation
128. A Pro12Ala substitution in PPARgamma2 associated with decreased receptor activity, lower body mass index and improved insulin sensitivity
129. The hormone resistin links obesity to diabetes
130. Membrane glycoprotein PC-1 and insulin resistance in non-insulin dependent diabetes mellitus
131. A polymorphism (K12Q) of the human glycoprotein PC-1 gene coding region is strongly associated with insulin resistance
132. Association between the human glycoprotein PC-1 gene and elevated glucose and insulin levels in a paired-sibling analysis
133. Structure of the insulin receptor substrate IRS-1 defines a unique signal transduction protein
134. Aminoacid polymoprhism of the insulin receptor substrate-1 in non-insulin-dependent diabetes mellitus
135. Insulin resistance: Interactions between obesity and a common variant of the insulin receptor substrate-1
136. Disruption of IRS-2 causes type 2 diabetes in mice
137. Disruption of insulin receptor substrate 2 causes type 2 diabetes because of liver insulin resistance and lack of compensatory beta-cell hyperplasia
138. Thiazolidinediones (PPARgamma agonists) but not PPARalpha agonists increase IRS-2 gene expression in 3T3-L1 and human adipocytes
139. Assignment of the gene encoding gycogen synthase to human chromosome 19, band q13.3
140. Isolation and characterization of the human muscle glycogen synthase gene
141. Association between polymorphism of the glycogen synthase gene and non-insulin-dependent diabetes mellitus
142. Association of the glycogen synthase locus 19q13 with NIDDM in Pima Indians
143. A paired sibling analysis of the XbaI polymorphism in the muscle glycogen synthase gene
144. Impact of the Xba1-polymorphism of the human muscle glycogen synthase gene on parameters of the insulin resistance syndrome in a Danish twin population
145. The stimulation-induced increase in skeletal muscle glycogen synthase content is impaired in carriers of the glycogen synthase XbaI gene polymorphism
146. Glycogen synthase: A putative locus for diet-induced hyperglycemia
147. The Finland-United States investigation of non-insulin-dependent diabetes mellitus genetics (FUSION) study. II. An autosomal genome scan for diabetes-related quantitative-trait loci
148. The human obesity gene map: The 1999 update
149. The genetics of type 2 diabetes
150. Identification of an obesity quantitative trait locus on mouse chromosome 2 and evidence of linkage to body fat and insulin on human homologous region 20q
151. Genomewide search for genes influencing percent body fat in Pima Indians: Suggestive linkage at chromosome 11q21-q22
152. A genome-wide search for human non-insulin-dependent (type 2) diabetes genes reveals a major susceptibility locus on chromosome 2
153. Mapping of a gene for type 2 diabetes associated with an insulin secretion defect by a genome scan in Finnish families
154. A susceptibility locus for early-onset non-insulin dependent (type 2) diabetes mellitus maps to chromosome 20q, proximal to the phosphoenolpyruvate carboxykinase gene
155. Type 2 diabetes: Evidence for linkage on chromosome 20 in 716 Finnish affected sib pairs
156. A gene conferring susceptibility to NIDDM in conjunction with obesity is located on chromosome 18p11.31
157. Genetic variation in the gene encoding calpain-10 is associated with type 2 diabetes mellitus
158. A calpain-10 gene polymorphism is associated with reduced muscle mRNA levels and insulin resistance